317 related articles for article (PubMed ID: 29110150)
1. The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT.
Kirkham AA; Eves ND; Shave RE; Bland KA; Bovard J; Gelmon KA; Virani SA; McKenzie DC; Stöhr EJ; Waburton DER; Campbell KL
Breast Cancer Res Treat; 2018 Feb; 167(3):719-729. PubMed ID: 29110150
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of acute exercise prior to doxorubicin on cardiac function of breast cancer patients: A proof-of-concept RCT.
Kirkham AA; Shave RE; Bland KA; Bovard JM; Eves ND; Gelmon KA; McKenzie DC; Virani SA; Stöhr EJ; Warburton DER; Campbell KL
Int J Cardiol; 2017 Oct; 245():263-270. PubMed ID: 28735755
[TBL] [Abstract][Full Text] [Related]
3. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
Kirkham AA; Paterson DI; Prado CM; Mackey JR; Courneya KS; Pituskin E; Thompson RB
BMC Cancer; 2018 Sep; 18(1):864. PubMed ID: 30176834
[TBL] [Abstract][Full Text] [Related]
6. Exercise preconditioning provides long-term protection against early chronic doxorubicin cardiotoxicity.
Hydock DS; Lien CY; Jensen BT; Schneider CM; Hayward R
Integr Cancer Ther; 2011 Mar; 10(1):47-57. PubMed ID: 21382960
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer.
Caram MEV; Guo C; Leja M; Smerage J; Henry NL; Giacherio D; Rubenfire M; Schott A; Davis M; Hayes DF; Van Poznak C; Cooney KA; Hertz DL; Banerjee M; Griggs JJ
Breast Cancer Res Treat; 2015 Jul; 152(1):163-172. PubMed ID: 26050157
[TBL] [Abstract][Full Text] [Related]
8. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
9. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide.
Kolaric K; Bradamante V; Cervek J; Cieslinska A; Cisarz-Filipcak E; Denisov LE; Donat D; Drosik K; Gershanovic M; Hudziec P
Oncology; 1995; 52(3):251-5. PubMed ID: 7715910
[TBL] [Abstract][Full Text] [Related]
11. Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients.
Bulten BF; Verberne HJ; Bellersen L; Oyen WJ; Sabaté-Llobera A; Mavinkurve-Groothuis AM; Kapusta L; van Laarhoven HW; de Geus-Oei LF
Cancer Chemother Pharmacol; 2015 Nov; 76(5):957-67. PubMed ID: 26400150
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction.
Narayan HK; French B; Khan AM; Plappert T; Hyman D; Bajulaiye A; Domchek S; DeMichele A; Clark A; Matro J; Bradbury A; Fox K; Carver JR; Ky B
JACC Cardiovasc Imaging; 2016 Oct; 9(10):1131-1141. PubMed ID: 27085442
[TBL] [Abstract][Full Text] [Related]
13. Identification of Clinical and Laboratory Variables Associated with Cardiotoxicity Events Due to Doxorubicin in Breast Cancer Patients: A 1-Year Follow-Up Study.
Simões R; Silva LM; de Oliveira AN; Alves MT; Pestana RMC; de Souza IDP; Oliveira HHM; Soares CE; Sabino AP; Gomes KB
Cardiovasc Toxicol; 2021 Feb; 21(2):106-114. PubMed ID: 32844368
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Gil-Gil MJ; Bellet M; Morales S; Ojeda B; Manso L; Mesia C; Garcia-Martínez E; Martinez-Jáñez N; Melé M; Llombart A; Pernas S; Villagrasa P; Blasco C; Baselga J
Breast Cancer Res Treat; 2015 Jun; 151(3):597-606. PubMed ID: 25981896
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
[TBL] [Abstract][Full Text] [Related]
16. Acute exercise protects against doxorubicin cardiotoxicity.
Wonders KY; Hydock DS; Schneider CM; Hayward R
Integr Cancer Ther; 2008 Sep; 7(3):147-54. PubMed ID: 18815146
[TBL] [Abstract][Full Text] [Related]
17. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
18. Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
Rigaud VO; Ferreira LR; Ayub-Ferreira SM; Ávila MS; Brandão SM; Cruz FD; Santos MH; Cruz CB; Alves MS; Issa VS; Guimarães GV; Cunha-Neto E; Bocchi EA
Oncotarget; 2017 Jan; 8(4):6994-7002. PubMed ID: 28052002
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab and doxorubicin-related cardiotoxicity and the cardioprotective role of exercise.
Wonders KY; Reigle BS
Integr Cancer Ther; 2009 Mar; 8(1):17-21. PubMed ID: 19174506
[TBL] [Abstract][Full Text] [Related]
20. Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity.
Mazzucchelli S; Bellini M; Fiandra L; Truffi M; Rizzuto MA; Sorrentino L; Longhi E; Nebuloni M; Prosperi D; Corsi F
Oncotarget; 2017 Jan; 8(5):8383-8396. PubMed ID: 28039473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]